AR063335A1 - Derivados de 4- (2- amino-1- hidroxietil) fenol como agonistas del receptor beta 2 adrenergico - Google Patents

Derivados de 4- (2- amino-1- hidroxietil) fenol como agonistas del receptor beta 2 adrenergico

Info

Publication number
AR063335A1
AR063335A1 ARP070104616A ARP070104616A AR063335A1 AR 063335 A1 AR063335 A1 AR 063335A1 AR P070104616 A ARP070104616 A AR P070104616A AR P070104616 A ARP070104616 A AR P070104616A AR 063335 A1 AR063335 A1 AR 063335A1
Authority
AR
Argentina
Prior art keywords
group
atom
hydrogen
atoms
alkyl
Prior art date
Application number
ARP070104616A
Other languages
English (en)
Inventor
Crespo Maria Isabel Crespo
Duran Carlos Puig
Tana Jordi Bach
Roig Silvia Gual
Munoz Alberto Ortega
Original Assignee
Almirall Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38084359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR063335(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Lab filed Critical Almirall Lab
Publication of AR063335A1 publication Critical patent/AR063335A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)

Abstract

La presente proporciona un compuesto de formula (1), en la que: R1 es un grupo seleccionado de -CH2OH, -NH(CO)H y R2 es un átomo de hidrogeno; o R1 junto con R2 forman el grupo -NH-C(O)-CH=CH- en el que el átomo de nitrogeno está unido el átomo de carbono en el anillo fenilo que soporta R1 y el átomo de carbono está unido al átomo de carbono en el anillo fenilo que soporta R2; R3a y R3b se seleccionan Independientemente del grupo consistente en átomos de hidrogeno y grupos alquilo C1-4, X e Y se seleccionen independientemente del grupo consistente en un enlace directo y un átomo de oxigeno; cada uno de n, m y q independientemente tiene un valor seleccionado de 0,1,2 y 3, p tiene un valor seleccionado de 1, 2 y 3; R4 y R5 se seleccionan Independientemente de átomos de hidrogeno, átomos de halogeno, alquilo C1-4, .alcoxi C1-4, -CONH2, -NHCONH2, -SR7, -SOR7, -SO2R7, -SO2NHR8 y los grupos de formulas (2) en los que R7 se selecciona de alquilo C1-4 y cicloalquilo C3-8 y R8 se selecciona de átomos de hidrogeno y grupos alquilo C1-4; R8 se selecciona del grupo consistente en átomos de hidrogeno, halogeno, alquilo C1-4 y alcoxi C1-4, o una de sus sales o solvatos o estereoisomeros farmacéuticamente aceptables.
ARP070104616A 2006-10-20 2007-10-18 Derivados de 4- (2- amino-1- hidroxietil) fenol como agonistas del receptor beta 2 adrenergico AR063335A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200602676A ES2302447B1 (es) 2006-10-20 2006-10-20 Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.

Publications (1)

Publication Number Publication Date
AR063335A1 true AR063335A1 (es) 2009-01-21

Family

ID=38084359

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104616A AR063335A1 (es) 2006-10-20 2007-10-18 Derivados de 4- (2- amino-1- hidroxietil) fenol como agonistas del receptor beta 2 adrenergico

Country Status (32)

Country Link
US (2) US20100168161A1 (es)
EP (1) EP2057122B1 (es)
JP (1) JP5411701B2 (es)
KR (1) KR101442279B1 (es)
CN (1) CN101522631B (es)
AR (1) AR063335A1 (es)
AT (1) ATE479659T1 (es)
AU (1) AU2007312573B2 (es)
BR (1) BRPI0715236A2 (es)
CA (1) CA2665376A1 (es)
CL (1) CL2007002956A1 (es)
CY (1) CY1110960T1 (es)
DE (1) DE602007008910D1 (es)
DK (1) DK2057122T3 (es)
ES (2) ES2302447B1 (es)
HK (1) HK1126487A1 (es)
HR (1) HRP20100602T1 (es)
IL (1) IL197294A (es)
MX (1) MX2009003802A (es)
NO (1) NO20091551L (es)
NZ (1) NZ575215A (es)
PE (1) PE20081263A1 (es)
PL (1) PL2057122T3 (es)
PT (1) PT2057122E (es)
RS (1) RS51482B (es)
RU (1) RU2451675C2 (es)
SI (1) SI2057122T1 (es)
TW (1) TWI413639B (es)
UA (1) UA97495C2 (es)
UY (1) UY30622A1 (es)
WO (1) WO2008046598A1 (es)
ZA (1) ZA200901355B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2226323A1 (en) 2009-02-27 2010-09-08 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
EP2360158A1 (en) 2010-02-18 2011-08-24 Almirall, S.A. Pyrazole derivatives as jak inhibitors
EP2380890A1 (en) 2010-04-23 2011-10-26 Almirall, S.A. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
EP2397482A1 (en) 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
WO2013113778A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113720A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113788A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
JP2015511940A (ja) 2012-02-03 2015-04-23 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 殺菌性ピリミジン化合物
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
EP2809659A1 (en) 2012-02-03 2014-12-10 Basf Se Fungicidal pyrimidine compounds
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2647627A1 (en) * 2012-04-02 2013-10-09 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
AR094797A1 (es) 2013-02-15 2015-08-26 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
CZ306252B6 (cs) * 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
CN112194586B (zh) * 2020-09-08 2023-03-10 青岛职业技术学院 一种沙丁胺醇二聚体的制备方法
CN112979632B (zh) * 2021-03-15 2022-08-30 台州学院 一种4-羟基-1,3-噻嗪-2-硫酮类化合物的合成方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3053865A (en) * 1958-03-19 1962-09-11 Merck & Co Inc Novel 16-alkyl and 16-alkylene steroids and processes
US3007923A (en) * 1959-01-22 1961-11-07 Lab Francais Chimiotherapie Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
US3104246A (en) * 1961-08-18 1963-09-17 Roussel Uclaf Process of preparation of beta-methasone
SE378109B (es) * 1972-05-19 1975-08-18 Bofors Ab
US4022776A (en) * 1974-01-31 1977-05-10 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxycarbostyril derivatives
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
US5648370A (en) * 1990-11-20 1997-07-15 Astra Pharmaceuticals Limited 7-(2-aminoethyl) benzothiazolones
ID24062A (id) * 1997-07-25 2000-07-06 Kissei Pharmaceutical Turunan-turunan asam aminoetilfenoksiasetat dan obat untuk mengurangi nyeri dan membantu penyingkiran dalam litiasis saluran air kencing
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6683115B2 (en) * 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
OA11558A (en) * 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
EP1497261B1 (en) * 2002-04-25 2007-12-19 Glaxo Group Limited Phenethanolamine derivatives
US6747043B2 (en) * 2002-05-28 2004-06-08 Theravance, Inc. Alkoxy aryl β2 adrenergic receptor agonists
NZ537206A (en) * 2002-06-27 2007-06-29 Astellas Pharma Inc Aminoalcohol derivatives
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4767842B2 (ja) * 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
TW200526547A (en) * 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
GB0324654D0 (en) * 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
WO2005121065A2 (en) * 2004-06-03 2005-12-22 Theravance, Inc. DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS
US7317023B2 (en) * 2004-07-21 2008-01-08 Theravance, Inc. Diaryl ether β2 adrenergic receptor agonists
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
EP1778626A1 (en) * 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US20060205949A1 (en) * 2005-03-10 2006-09-14 Theravance, Inc. Crystalline forms of a biphenyl compound
ES2265276B1 (es) * 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
UY32297A (es) * 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2221297A1 (en) * 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases
EP2221055A1 (en) * 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function
US8597295B2 (en) * 2010-04-12 2013-12-03 Covidien Lp Surgical instrument with non-contact electrical coupling

Also Published As

Publication number Publication date
HRP20100602T1 (hr) 2010-12-31
RS51482B (en) 2011-04-30
US20100168161A1 (en) 2010-07-01
AU2007312573B2 (en) 2013-01-10
US20150210643A1 (en) 2015-07-30
MX2009003802A (es) 2009-06-04
JP2010506870A (ja) 2010-03-04
DK2057122T3 (da) 2010-12-06
PT2057122E (pt) 2010-12-09
CA2665376A1 (en) 2008-04-24
CN101522631B (zh) 2013-06-12
RU2451675C2 (ru) 2012-05-27
RU2009118825A (ru) 2010-11-27
IL197294A (en) 2014-03-31
EP2057122B1 (en) 2010-09-01
SI2057122T1 (sl) 2011-01-31
EP2057122A1 (en) 2009-05-13
TW200827338A (en) 2008-07-01
ZA200901355B (en) 2010-04-28
ES2302447A1 (es) 2008-07-01
CY1110960T1 (el) 2012-05-23
NZ575215A (en) 2011-02-25
PL2057122T3 (pl) 2011-03-31
CL2007002956A1 (es) 2008-02-15
TWI413639B (zh) 2013-11-01
WO2008046598A8 (en) 2009-04-30
CN101522631A (zh) 2009-09-02
UA97495C2 (ru) 2012-02-27
KR101442279B1 (ko) 2014-10-02
KR20090073129A (ko) 2009-07-02
ES2302447B1 (es) 2009-06-12
BRPI0715236A2 (pt) 2013-06-25
WO2008046598A1 (en) 2008-04-24
PE20081263A1 (es) 2008-09-04
HK1126487A1 (en) 2009-09-04
UY30622A1 (es) 2008-02-29
NO20091551L (no) 2009-07-15
ATE479659T1 (de) 2010-09-15
IL197294A0 (en) 2009-12-24
DE602007008910D1 (de) 2010-10-14
ES2352580T3 (es) 2011-02-21
JP5411701B2 (ja) 2014-02-12
AU2007312573A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
AR063335A1 (es) Derivados de 4- (2- amino-1- hidroxietil) fenol como agonistas del receptor beta 2 adrenergico
AR060661A1 (es) Derivados de 4-(2-amino-1-hidroxietil) fenol como agonistas del receptor 2 adrenergico
AR058005A1 (es) Derivados fluorados de 4-(2- amino-1-hidroxietil) fenol como agonistas del receptor beta 2 adrenergico
AR087919A1 (es) Heterociclos biciclicos como inhibidores de irak4
CO5680412A2 (es) Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino
PE20130155A1 (es) Derivados de ariletinilo
AR078397A1 (es) Compuestos heterociclicos antivirales
AR064355A1 (es) Herbicidas derivados de isoxazol
AR076900A1 (es) Derivados heterociclicos nitrogenados utiles como agentes antivirales, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del vhc
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
CO6321244A2 (es) Pirrolopiridinas como inhibidores de cinasa
UY31439A1 (es) Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenérgico b(beta)2
CO6231035A2 (es) Novedoso compuesto heteromonociclico que tiene propiedades superiores como agente farmaceutico
ES2570756T3 (es) Derivados pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa
ES2640911T3 (es) Cicloalquilnitrilpirazolcarboxamidas como inhibidores de la quinasa Janus
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
ES2586527T3 (es) Compuestos heterocíclicos y uso de los mismos como moduladores del receptor de tirosina quinasas de tipo III
AR076754A1 (es) Dihidropirimidinas y proceso de obtencion de las mismas
ECSP099395A (es) Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico
AR076810A1 (es) Compuestos anticancerigenos de amino pirimidina
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
AR088829A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR069796A1 (es) Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen
ES2630079T3 (es) Moduladores de la ruta del complemento y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure